Protalix BioTherapeutics (PLX) Other Operating Expenses (2010 - 2026)

Protalix BioTherapeutics' Other Operating Expenses history runs 13 years deep, the most recent figure standing at -$7.2 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 11936.67% year-over-year to -$7.2 million in Q1 2026; TTM through Mar 2026 was -$17.3 million, a 630.16% decrease from a year earlier, with the FY2025 full-year figure at -$10.3 million, down 38.02% from the prior year.
• Other Operating Expenses slipped to -$7.2 million in Q1 2026 per PLX's latest filing, from -$6.5 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $1.8 million in Q3 2024 and bottomed at -$7.2 million in Q1 2026.
• The 3-year median for Other Operating Expenses is -$2.0 million (2025), against an average of -$2.5 million.
• Across the five-year window, Other Operating Expenses decreased 25.0% in 2025 and sank 11936.67% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at -$5.2 million in 2024, then decreased by 25.0% to -$6.5 million in 2025, then dropped by 10.58% to -$7.2 million in 2026.
• Per Business Quant, the three latest PLX Other Operating Expenses figures stand at -$7.2 million (Q1 2026), -$6.5 million (Q4 2025), and $394000.0 (Q3 2025).